SAN DIEGO , July 29, 2010 (GLOBE NEWSWIRE) -- Entest BioMedical Inc. (OTCBB:ENTB) today announced that it is currently finalizing the Company’s protocols in preparation for a 10 dog safety study required for marketing ImenVax(TM) I, an immuno-therapeutic cancer vaccine for dogs being developed by the Company. The Company expects to commence the safety study in late September 2010.
Entest believes this safety study can be initiated and completed within the next six months paving the way for entry into the veterinary market with its first therapeutic product. The Company has three related immunotherapeutic cancer vaccines currently under development.
ImenVax(TM) I, the first of these three vaccines, has the potential to be commercially available within the next 12 months.
David Koos, Chairman & CEO of Entest BioMedical, stated, “We are extremely excited about the progress we are making. Canine cancer represents a major area of focus for Entest as it is estimated that one in every four dogs will develop cancer in its lifetime. It is also estimated that 50% of all dogs over 10 years of age will likely die from cancer absent better therapeutic interventions.”
Mr. Koos continued, “Entest has adopted a ‘veterinary first’ approach to product development. This means our primary focus is on the veterinary market for oncology and other therapeutics -- not the human market. The benefits of this approach are two-fold. First, we believe these therapies address a sizeable and underserved market for pets and other animals. Second, our veterinary focus allows for commercialization that is orders of magnitude faster, with less uncertainty than completing the lengthy FDA process required for approval of human therapeutics. Moreover, once we have demonstrated ‘proof-of-concept’ in animals, along with generating sustainable revenue and cash flow, we will be in a much stronger position to explore the market potential for our cancer vaccine in the human market through licensing agreements and joint venture partnerships. In the decade or more it may take to successfully move a single therapeutic drug candidate through the FDA process for use in humans, we may, with significantly less capital outlay, be able to take literally dozens of drug candidates into the veterinary market and with successful commercialization, generate cash flow and shareholder returns long before the human drug candidate approaches completion of the regulatory approval process noting that FDA approvals are far from certain even when the data is quite promising.”
About Entest BioMedical (www.entestbio.com)
Entest BioMedical is a developer of veterinary medicines that harness the animal’s own reparative/immunological mechanisms. The company’s products include immuno-therapeutic cancer vaccines for canines (ImmenVax(TM) I, II & III) and a stem cell therapy treatment for Chronic Obstructive Pulmonary Disease (COPD) in thoroughbred race horses (ENT‐576(TM)). The company’s Immunotherapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. The immuno-therapeutic cancer vaccine utilizes the animals own cancer cells in order to induce an immune response. The company’s proprietary ENT‐576(TM) program for COPD incorporates “homing” stimulator technology that directs stem cells to diseased lung tissue. This approach could cause damaged tissue to regenerate with potential to alleviate symptoms and reverse lung damage.
About Crescendo Communications, LLC (www.crescendo-ir.com)
Crescendo Communications, LLC, headquartered in New York City, is an emerging leader within the investor relations industry. The principals of Crescendo have represented hundreds of companies across all market caps and industries. The firm was founded on a strategic and professional approach to investor relations that builds awareness of public companies through tailored outreach programs that target institutional investors, analysts, and the financial media. Crescendo’s approach is centered around properly educating investors and cultivating trust between the firm’s clients and the Wall Street community.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT: Crescendo Communications, LLC David K. Waldman John J. Quirk, Jr. (212) 671-1020 aehi@crescendo-ir.com
